Data stays in Europe. Only the analysis travels.
INNOONE is one of up to ten Korean AI companies selected by Gyeonggi Province for its AI Cluster Global Programme (Europe). We come to Helsinki with a PoC design that already fits Finnish and EU data rules — and one clear ask.
NHS GMS (UK), Hartwig WGS reimbursement (NL), FinnGen 500,000 (FI), Danish NGC, Estonian Biobank.
Reports take weeks; no platform links diagnosis to drug recommendation and discovery.
GDPR, EU AI Act, national secondary-use laws → federated analysis, not data export.
Europe already pays for one gene. We answer from the whole genome.
DPYD testing before 5-FU chemotherapy is standard of care across Europe — a single-gene answer that health systems reimburse because it prevents deaths. INNOONE delivers that certainty for every actionable gene at once: pharmacogenomics, hereditary cancer and cardiovascular risk, carrier status — and re-analyses the same genome as evidence grows.
Clinics & genome centres
Research-use (RUO) interpretation PoC on your WGS data: concordance report, turnaround in days, return-of-results demo. Pipeline runs inside your environment.
Biobanks & national programmes
Rare-disease and pharmacogenomic endpoints first; participant return-of-results (INOME) and pseudonymised federated analysis (INODE).
Pharma & ADC developers
INNODAC antigen / antibody target discovery and INNOVA structure-based repurposing — joint target PoC on your indication.
Finland-ready
Not a first visit. In 2025 our founders analysed FinnGen's governance and public data for Korea's Ministry of Science and ICT and the national bio-big-data committee.
- What we knowGreen (aggregate) vs Red (individual-level) data · Findata permits · certified Sandbox inside EU/EEA · Biobank Act 688/2012 · Secondary Use Act 552/2019 · 12-month partner embargo.
- What we didDownloaded FinnGen R12 public GWAS summary statistics (21.3 million variants) and ran our own pipeline — top variants, pathway enrichment (Peters-plus syndrome / O-glycosylation), 106 new rare-disease endpoints reviewed.
- What we proposeA 12-week RUO interpretation PoC with a Finnish hospital or biobank: INNOVANOME runs inside the partner's environment via INODE — no genome leaves Finland.
- Who we want to meetHUS Helsinki University Hospital · FIMM (FinnGen) · Business Finland · Health Capital Helsinki · Orion · Nordic life-science investors.
One European PoC partner and Nordic / European investors
- One clinical or biobank partner for a research-use interpretation PoC in 2027
- Nordic and European life-science VCs to join our USD 3.6M seed extension (2026 H2 – 2027)
- One pharma / ADC target-discovery discussion
Roadmap: Land → Expand → Scale
Helsinki first
- Slush 2026 meetings · Gyeonggi demo day
- Q1 2027: PoC MOU ×1–2, investor LOI ×2
- EU PoC: INNOVANOME / INNOPORTAL (RUO)
- INODE federated analysis — no data transfer
Regulated product
- CE marking (MDR/IVDR) + AI Act conformity
- EU entity (Helsinki / Copenhagen), local BD hire
- Series A with EU investors
National programmes
- Hospital licences after CE
- National WGS programme tenders (NHS · Hartwig · DNGC)
- Pharma target licensing
Meet us in Helsinki
16–20 November 2026 in Helsinki, or online any time. Send a short note with your interest and preferred slot — we reply within two business days.